It seems a simple nexus between subsidising clinical software (OS or commercial) that meets an accredited standard (input from us!) by paying for use of 3rd party data, e.g. drug interactions, coding systems etc. would set a market benchmark with relatively small govt expense. The rest of the costs of development and support would be met in the usual competitive way, which would allow for OS products to flourish as they would be the most likely to meet the standards without the impediment of users having to pay for the use of external databases, therefore would probably also be free.
Jim
_______________________________________________
Gpcg_talk mailing list
[email protected]
http://ozdocit.org/cgi-bin/mailman/listinfo/gpcg_talk

Reply via email to